Shanghai, December 16, 2022 - Aon Group, a global leading professional services firm, recently released its list of 2022 Best ESG Employers in China. Hasten Biopharma was awarded the " 2022 Aon China Best ESG Employer Agile Organization Award" for its efforts on sustainable organization building and innovation achievements.

On the morning of Nov. 23, the groundbreaking ceremony for Hasten Biopharma Hefei Production Base project (Yi Bo Sen Pharmaceutical Co., Ltd.) was held in Feidong, Hefei. Yuan Fei, member of the Standing Committee of Hefei Municipal Committee, attended the ceremony and announced the full start of the project. Summer Xia, CEO of Hasten Biopharma, Jiang Xin, General Manager of Hefei Industry Investment Group and Chairman & General Manager of Hefei Industry Investment Capital, Yao Fei, Secretary of Feidong County, Zhang Hong, CEO of RMB Business Group of CBC Group, Annie Lee, Chairman of the Board of Directors of Hasten Biopharma and Managing Director of CBC Group, Zhang Bo, Managing Director of CBC Broup and Director of Hasten Biopharma were present. Vice Governor of Feidong County, Ma Juanshu, hosted the ceremony. Representatives from related institutions of Feidong County and Hefei City participate in the start-up activities.

Hasten Biopharma and Sinopharm Group Jiangsu Company Limited signed a strategic cooperation agreement in Suzhou Jiangsu Province on September 27th 2022. The two companies will work together to create a closed-loop medical service by using innovative digital marketing methods, enhance the coverage of digital platform through the efficient commercialization capability of Sinopharm Jiangsu, and assist patients in the whole course of health management.

Hasten Bioparma and Jointown Pharmaceutical Group Co. (Jointown Group) signed a strategic cooperation agreement. The two companies will work together to build an out-of-hospital chronic disease management ecosystem, enhance retail terminal coverage through efficient commercialization capabilities, improve out-of-hospital patient access to medicines, and work together to benefit more patients with chronic diseases.

In recent years, the number of incidences, illnesses and mortality by chronic diseases has been increasing, and chronic diseases such as cardiovascular and cerebrovascular diseases are a serious threat to the health of Chinese people, especially the elderly population, making it particularly important to focus on the unmet needs of chronic diseases.

- CBC Group further builds global healthcare platform to address unmet medical needs - Hasten Biopharma accelerates its layout to provide more innovative drugs to Chinese patients